FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904010150> ?p ?o ?g. }

• W2904010150 endingPage "3451" @default.
• W2904010150 startingPage "3451" @default.
• W2904010150 abstract "Abstract Background and aims. Data collection in clinical trials is becoming complex, with huge amount of clinical and biological variables that need to be recorded, verified and analyzed to confirm obvious and identify unexpected associations. Outside the medical field, data warehouses (DWs) are widely employed to achieve these objectives. To verify whether DWs might be useful for data quality and association analysis, a team of clinicians, biologists, statisticians and biomedical engineers developed DELPHI (“Data ELaboration to Predict Hypothetical assocIations”). The tool has been suited to a large clinical trial from the Fondazione Italiana Linfomi (FIL), including all the clinical, biological and mutational features collected both in the trial and in the ancillary studies. Herein we present the first results, related to baseline variables: 1) creation of a broad DW (including 350 variables for 300 patients, thus > 105data); 2) data harmonization and quality control; 3) discovery of unexpected associations and (in a later phase) outcome correlations; 4) results visualization. Methods. Data were retrieved from electronic case reporting forms (eCRF) of the phase III, multicenter “FIL-MCL0208” trial (NCT02354313) for younger, untreated mantle cell lymphoma patients [Cortelazzo, EHA 2015], now at the second interim analysis. DW was created with Mysql®, a relational database management system, already used in many apps. DW filling, data cleaning and statistical analysis were performed via Matlab®. For this preliminary analysis 62 baseline features from 300 subjects were organized in groups of demographics, clinical, laboratory, pathological, minimal residual disease, gene expression profiling (GEP) and mutational variables. A first data quality control was performed. Secondly, a team of 3 lymphoma experts claimed the expected associations among about 1860 couples of features conveniently categorized. The original series was randomly divided in two subsets (200 vs 100 subjects): the first used for discovery and the second as a validation set. For each subset, couples were screened by Chi-square and Fisher's test as appropriate (p Results. Quality Control: DELPHI allowed cross comparison analysis and detected many incongruities in eCRF, prompting request for queries to clinical centers, which allowed data corrections - e.g. data quality increase has been recorded for classical laboratory (+7%), biological (+40%) and clinical data (up to 99.6% of correctness). Testing associations: DELPHI identified 231/1860 (12%) associations in the discovery set, of whom 64% (149/231) were confirmed in the validation set. Among these mismatches, main contribution is imputed to associations between clinical and laboratory data with baseline tumor burden by quantitative PCR, qPCR, (n=21) and mutational data (n=11). The clinical team classified as “expected” 242/1860 variables matches (13%), 54% of whom were confirmed by DELPHI (Figure 1A). The thickest ribbons have V>0.5: among these, bone marrow tumor invasion (BMinf) by immunohistochemistry with nodal (NLTB) and extra-nodal (ENLTB) tumor burden at CT scan; Lymphocytes with BMinf by Flow cytometry (Flow). TP53 mutations and blastoid histology with a V=0.39. Finally, discovery of novel associations is shown in Figure 1B. 54 of 1860 (3%) matches were identified by DELPHI as statistically significant unexpected associations: the thickest ribbons have V>0.35. Among these, MIPI, albumin and LDH with Hemoglobin; BMinf by qPCR with MIPIc. Moreover, TP53 mutations and GammaGT (V=0.34), as well as NOTCH1 mutations with ALkaline-Phosphatase (V=0.35) and MIPIb with Beta2 Microglobulin, B2M (V=0.33). Discussion. DELPHI DW is a powerful tool that identifies novel putative associations between clinical and biological features. In order to consider confounding interactions and multiple comparison issues, every association needs further validation on independent data series. The association of baseline data with post-treatment outcomes is ongoing. Download : Download high-res image (321KB) Download : Download full-size image Figure 1 . Disclosures Galimberti: Novartis: Speakers Bureau; Incyte: Speakers Bureau; Bristol-Myers Squibb: Speakers Bureau; Pfizer: Speakers Bureau. Gaidano: AbbVie: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Roche: Consultancy, Honoraria. Boccadoro: AbbVie: Honoraria; Amgen: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria, Research Funding; Sanofi: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Mundipharma: Research Funding." @default.
• W2904010150 created "2018-12-22" @default.
• W2904010150 creator A5000403848 @default.
• W2904010150 creator A5001285087 @default.
• W2904010150 creator A5011367557 @default.
• W2904010150 creator A5012645361 @default.
• W2904010150 creator A5012791314 @default.
• W2904010150 creator A5015790909 @default.
• W2904010150 creator A5016232808 @default.
• W2904010150 creator A5018139001 @default.
• W2904010150 creator A5027012379 @default.
• W2904010150 creator A5034220119 @default.
• W2904010150 creator A5036223053 @default.
• W2904010150 creator A5037889066 @default.
• W2904010150 creator A5041745367 @default.
• W2904010150 creator A5051021130 @default.
• W2904010150 creator A5051195250 @default.
• W2904010150 creator A5053891408 @default.
• W2904010150 creator A5060801603 @default.
• W2904010150 creator A5061736991 @default.
• W2904010150 creator A5072819543 @default.
• W2904010150 creator A5073179633 @default.
• W2904010150 creator A5076353357 @default.
• W2904010150 creator A5091091710 @default.
• W2904010150 date "2017-12-08" @default.
• W2904010150 modified "2023-10-11" @default.
• W2904010150 title "Delphi, a Data Warehouse to Discover Associations between Variables in Clinical Trials: Application to the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial" @default.
• W2904010150 doi "https://doi.org/10.1182/blood.v130.suppl_1.3451.3451" @default.
• W2904010150 hasPublicationYear "2017" @default.
• W2904010150 type Work @default.
• W2904010150 sameAs 2904010150 @default.
• W2904010150 citedByCount "1" @default.
• W2904010150 countsByYear W29040101502019 @default.
• W2904010150 crossrefType "journal-article" @default.
• W2904010150 hasAuthorship W2904010150A5000403848 @default.
• W2904010150 hasAuthorship W2904010150A5001285087 @default.
• W2904010150 hasAuthorship W2904010150A5011367557 @default.
• W2904010150 hasAuthorship W2904010150A5012645361 @default.
• W2904010150 hasAuthorship W2904010150A5012791314 @default.
• W2904010150 hasAuthorship W2904010150A5015790909 @default.
• W2904010150 hasAuthorship W2904010150A5016232808 @default.
• W2904010150 hasAuthorship W2904010150A5018139001 @default.
• W2904010150 hasAuthorship W2904010150A5027012379 @default.
• W2904010150 hasAuthorship W2904010150A5034220119 @default.
• W2904010150 hasAuthorship W2904010150A5036223053 @default.
• W2904010150 hasAuthorship W2904010150A5037889066 @default.
• W2904010150 hasAuthorship W2904010150A5041745367 @default.
• W2904010150 hasAuthorship W2904010150A5051021130 @default.
• W2904010150 hasAuthorship W2904010150A5051195250 @default.
• W2904010150 hasAuthorship W2904010150A5053891408 @default.
• W2904010150 hasAuthorship W2904010150A5060801603 @default.
• W2904010150 hasAuthorship W2904010150A5061736991 @default.
• W2904010150 hasAuthorship W2904010150A5072819543 @default.
• W2904010150 hasAuthorship W2904010150A5073179633 @default.
• W2904010150 hasAuthorship W2904010150A5076353357 @default.
• W2904010150 hasAuthorship W2904010150A5091091710 @default.
• W2904010150 hasConcept C105795698 @default.
• W2904010150 hasConcept C111919701 @default.
• W2904010150 hasConcept C124101348 @default.
• W2904010150 hasConcept C126322002 @default.
• W2904010150 hasConcept C133462117 @default.
• W2904010150 hasConcept C135572916 @default.
• W2904010150 hasConcept C162324750 @default.
• W2904010150 hasConcept C176217482 @default.
• W2904010150 hasConcept C19527891 @default.
• W2904010150 hasConcept C21547014 @default.
• W2904010150 hasConcept C24756922 @default.
• W2904010150 hasConcept C2522767166 @default.
• W2904010150 hasConcept C2777525834 @default.
• W2904010150 hasConcept C2779338263 @default.
• W2904010150 hasConcept C2779495148 @default.
• W2904010150 hasConcept C33923547 @default.
• W2904010150 hasConcept C41008148 @default.
• W2904010150 hasConcept C535046627 @default.
• W2904010150 hasConcept C61943457 @default.
• W2904010150 hasConcept C71924100 @default.
• W2904010150 hasConcept C91790935 @default.
• W2904010150 hasConceptScore W2904010150C105795698 @default.
• W2904010150 hasConceptScore W2904010150C111919701 @default.
• W2904010150 hasConceptScore W2904010150C124101348 @default.
• W2904010150 hasConceptScore W2904010150C126322002 @default.
• W2904010150 hasConceptScore W2904010150C133462117 @default.
• W2904010150 hasConceptScore W2904010150C135572916 @default.
• W2904010150 hasConceptScore W2904010150C162324750 @default.
• W2904010150 hasConceptScore W2904010150C176217482 @default.
• W2904010150 hasConceptScore W2904010150C19527891 @default.
• W2904010150 hasConceptScore W2904010150C21547014 @default.
• W2904010150 hasConceptScore W2904010150C24756922 @default.
• W2904010150 hasConceptScore W2904010150C2522767166 @default.
• W2904010150 hasConceptScore W2904010150C2777525834 @default.
• W2904010150 hasConceptScore W2904010150C2779338263 @default.
• W2904010150 hasConceptScore W2904010150C2779495148 @default.
• W2904010150 hasConceptScore W2904010150C33923547 @default.
• W2904010150 hasConceptScore W2904010150C41008148 @default.
• W2904010150 hasConceptScore W2904010150C535046627 @default.
• W2904010150 hasConceptScore W2904010150C61943457 @default.
• W2904010150 hasConceptScore W2904010150C71924100 @default.
• W2904010150 hasConceptScore W2904010150C91790935 @default.

• next